

510(k) and De Novo Submissions Workshop

Virtual Event

February 8 - 10, 2022 *Schedule Reflected in Eastern Time

February 8, 2022

11:00 am – 11:05 am Welcome and Introductions

11:05 am – 11:50 am The Law and Regulations

• 510(k) definition

- 510 and 513 FDCA
- Guidance for 510(k): general & product specific
 - How to find it
 - o How to use it
- Different types of 510(k)s; which to use
- Review of bundling 510(k)s
- FDA Product Codes activity

11:50 am – 12:35 pm 510(k) Strategy and Planning

- Staff involved
- Role of each function
- RA responsibilities
- Use of guidance
- Global considerations
- Pre-submissions
- Predicates
- Breakthrough Devices Program
- Safer Technologies Program

12:35 pm – 12:50 pm Q&A

12:50 pm – 1:05 pm Break

1:05 pm – 2:20 pm Preparing the Submission

•

- General information including how to select a predicate device
- Assembling the 510(k)
- eCopy

2:20 pm – 2:35 pm Break

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



| 2:35 pm – 3:50 pm | The FDA Review Process How it works at FDA FDA/industry interactions Refuse to Accept Submission Issue meetings FDA holds Interactive review Least Burdensome flag Current pilots |
|---------------------|---|
| 3:50 pm – 4:20 pm | CDRH Ombudsman's Office Roles & Responsibilities Appeals Process |
| 4:20 pm – 4:35 pm | Q&A |
| February 9, 2022 | |
| 11:00 am – 11:01 am | Welcome |
| 11:01 am – 12:20 pm | Clearance: Launch and After What clearance does and does not mean Promotional practices for 510(k) devices FDA FTC Complaint Handling and MDRs When to File a New 510(k) for Device Modifications Catch-up 510(k)s |
| 12:20 pm – 12:30 pm | Q&A |
| 12:30 pm – 12:45 pm | Break |
| 12:45 pm – 1:15 pm | Definition of a De Novo Final Rule on De Novo When De Novo is used Differentiation from 510(k) |

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



| 1:15 pm – 1:45 pm | Regulatory Strategy for De Novo Key eligibility criteria Benefit-risk analysis |
|--------------------------|--|
| 1:45 pm – 2:15 pm | Preparing the De Novo Submission Content Assembling the submission |
| 2:15 pm – 2:30 pm | Q&A |
| 2:30 pm – 2:45 pm | Break |
| 2:45 pm – 3:15 pm | FDA Review Process for De Novo Use of Pre-Submission meeting User Fee |
| 3:15 pm – 3:45 pm | Maintenance of a Granted De Novo Post-market requirements Classification Order De Novo database, granting order, decision summary Use as a predicate |
| 3:45 pm – 4:00 pm | Q&A |
| 4:00 pm | Closing Remarks and Adjourn |
| <u>February 10, 2022</u> | |
| 12:00 pm – 1:15 pm | Applied Learning and Discussion Hypothetical Case Study Review Facilitated Breakout Group Deep Dive Key Takeaways Final Program Q&A |

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.